The company is pitching the test as a way to improve the safety and availability of blood.
Roche wins FDA approval for first molecular malaria blood donor screening test Read More »
On March 26th, the US FDA granted approval for Merck’s WINREVAIR™ (sotatercept-csrk), marking a significant milestone in pulmonary arterial hypertension (PAH) treatment.
An ActRIIA Fusion Protein Got FDA Approved for PAH Treatment Read More »
El vapeo se ha convertido en los últimos años en la alternativa más popular al consumo tradicional de tabaco. Según los datos de la encuesta EDADES elaborada por el Ministerio de Sanidad en España, el 10% de la población de 15 a 64 años (12, …
La marca OXVA revoluciona la forma de vapear de manera más ecológica y saludable Read More »
Kodiak Sciences Inc., reported business highlights and financial results for the quarter and year ended December 31, 2023.
DarioHealth Corp., a leader in the global digital health market, reported financial results for the fourth quarter 2023 and the full year 2023 and provided a corporate and commercial update.
DarioHealth Reports Fourth Quarter and Full-Year 2023 Financial and Operating Results Read More »
Merck, known as MSD outside of the United States and Canada, announced that the European Commission has approved KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with platinum-containing chemotherapy as neoadjuvant treatment, then continued as monotherapy as adjuvant treatment, for resectable non-small cell lung cancer at high risk of recurrence in adults.
Hangzhou Tigermed Consulting Co., Ltd., a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annual results for the year ended December 31, 2023.
Stoke Therapeutics, Inc. announced the pricing of its upsized underwritten public offering of 5,555,557 shares of its common stock at a price to the public of $13.50 per share and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 3,703,730 shares of its common stock
Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering Read More »
Vicore Pharma Holding AB announced multiple presentations at the 2024 American Thoracic Society International Conference, including an oral late-breaking presentation of the final Phase 2a AIR data of buloxibutid in patients suffering from idiopathic pulmonary fibrosis.
Virion Therapeutics, LLC announced promising safety results from the first-ever human data from its novel, first-in-class, checkpoint modifier immunotherapy, VRON-0200, for HBV functional cure, presented by Professor Grace Wong, M.D., from the Chinese University of Hong Kong, as a late breaker oral presentation at the 33rd Annual Meeting of APASL in Kyoto, Japan.
